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Abstract 
Background:  Contralateral prophylactic mastectomy (CPM) rates have significantly 
increased in recent years and may reflect an exaggerated perceived benefit from the 
procedure.  The objective of this study was to evaluate the magnitude of the survival 
benefit of CPM for women with unilateral breast cancer.   
 
Methods:  We developed a Markov model to simulate survival outcomes after CPM and 
no CPM among women with stage I or II breast cancer without a BRCA mutation.  
Probabilities for developing contralateral breast cancer (CBC), dying from CBC, dying 
from primary breast cancer, and age-specific mortality rates were estimated from 
published studies.  We estimated life expectancy (LE) gain, 20-year overall survival, and 
disease-free survival with each intervention strategy among cohorts of women defined by 
age, estrogen receptor (ER) status, and stage of cancer. 
 
Results:  Predicted LE gain from CPM ranged from 0.13 to 0.59 years for women with 
stage I breast cancer and 0.08 to 0.29 years for those with stage II breast cancer.  
Absolute 20-year survival differences ranged from 0.56% to 0.94% for women with stage 
I breast cancer and 0.36% to 0.61% for women with stage II breast cancer.  CPM was 
more beneficial among younger women, stage I, and ER-negative breast cancer.  
Sensitivity analyses yielded a maximum 20-year survival difference with CPM of only 
1.45%. 
 
  iv 
 
Conclusion:  The absolute 20-year survival benefit from CPM was less than 1% among 
all age, ER status, and cancer stage groups.  Estimates of LE gains and survival 
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INTRODUCTION 
The use of contralateral prophylactic mastectomy (CPM) among women with unilateral 
breast cancer has markedly increased in the United States during the past decade. [1-5] 
These trends have been observed in retrospective single-center studies,[1, 3] national 
population databases,[4, 5] and state cancer registries. [2] Similar trends have not been 
observed in Europe. [6, 7]   Breast cancer patients report that the main reason they choose 
CPM is worry about the risk of contralateral breast cancer (CBC),[8] yet they tend to 
substantially overestimate their risk of developing CBC. [9] CPM reduces the risk of 
CBC by about 90%, [10-14] but the overall survival benefit is unclear. [15-17] 
Long-term survival in women with unilateral breast cancer treated with or without 
CPM depends upon several factors including mortality of the primary breast cancer, risk 
of CBC, stage and mortality of the CBC, and the individual patient’s overall life 
expectancy.  Prospective randomized trials comparing CPM with no CPM are not 
feasible.  Retrospective studies evaluating a potential survival benefit with CPM are 
limited by short follow-up, potential selection bias, and lack of important clinical 
information. [15, 16, 18]  
The primary objective of this study was to assess the magnitude of the survival 
benefit of CPM among women with unilateral breast cancer using a simulated decision-
analytic Markov model.  Our aim was to provide projected long-term survival 
information by using a simulated Markov model for physicians and their patients when 
discussing breast cancer risk reduction strategies.  
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METHODS 
Model Design  
A Markov model [19] is a recursive decision tree that guides a hypothetical cohort 
between mutually exclusive health states depending on transition probabilities obtained 
from published data.  We developed a Markov state-transition model to simulate survival 
outcomes after CPM and no CPM for women with stage I and II breast cancer without 
BRCA mutations (Figure 1; appendix). The model simulates the long-term prognosis of 
hypothetical cohorts of women with newly diagnosed unilateral breast cancer under two 
scenarios: (1) CPM (i.e., double mastectomy) and (2) no CPM (assuming that women 
undergo either lumpectomy with radiation therapy or unilateral mastectomy).  We 
projected the benefit of CPM for cohorts of women defined by age at breast cancer 
diagnosis (40, 50, or 60 years), stage of primary breast cancer (I, II), and estrogen 
receptor (ER) status (positive, negative).   
The model tracks each cohort of women through health states over time.  Each 
year following treatment of the ipsilateral cancer, women may die from their primary 
breast cancer, develop CBC, or experience no adverse event.  After development of CBC, 
women are at an increased risk of dying from breast cancer (i.e., the risk associated with 
their ipsilateral and contralateral cancers).  Data from the 2008 life tables for US women 
were used to incorporate the age-specific annual risk of dying from other causes. [20] 
Model output for each strategy consisted of life expectancy (LE), overall survival, and 
disease-free survival. The model was programmed using TreeAge Pro 2012 (TreeAge 
Software, Williamstown, MA) 
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Data Sources 
The probabilities used in baseline analyses and the ranges evaluated in sensitivity 
analyses are listed in Table 1. 
Cancer Incidence and Prognosis 
Primary Breast Cancer.  We derived stage-specific breast cancer mortality rates from 
the relative survival curves reported in SEER. [21] We used SEER stat[22] to obtain 20 
year-relative survival curves for patients with stage I or II breast cancer, where stage was 
defined by the American Joint Committee on Cancer SEER modified staging system.  
SEER reports a breast-cancer-specific mortality risk (i.e., 1- relative survival percentage) 
for women with stage I breast cancer of 1.8% at 10 years and 10.0% at 20 years.  For 
women with stage II breast cancer, cancer-specific mortality was 23.1% at 10 years and 
42.2% at 20 years. [22]   
Contralateral Breast Cancer.  We assumed the stage-specific mortality associated with 
CBC was the same as reported by SEER.  For patients who developed CBC we added the 
stage-specific cancer mortality rate of their ipsilateral cancer to the stage-specific cancer 
mortality rate of their contralateral cancer.   
Several studies have evaluated the risk of developing CBC [23-26]. For our base-
case values, we used the recent meta-analysis from the Early Breast Cancer Trialists’ 
Collaborative Group (EBCTCG) that reported an annual probability of invasive CBC of 
about 0.4% for patients with ER-positive breast cancer treated with tamoxifen and about 
0.5% for patients with ER-negative breast cancer.  All age, tumor, and treatment 
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subgroups had probabilities less than 0.7% per year. [26] We assumed that every woman 
in our cohort with ER-positive breast cancer was treated with endocrine therapy for our 
base-case analysis.  Therefore, in our model at baseline we used an annual probability of 
developing CBC of 0.4% in ER- positive patients and 0.5% in ER-negative patients, 
varying from 0.2% to 0.7% in our sensitivity analysis to capture uncertainty and 
differences to treatment adherence to endocrine therapy.   
Contralateral Breast Cancer Stage.  Using the Oregon State Cancer Registry database, 
Quan et al. [27] reported that over 90% of CBC’s were either ductal carcinoma in situ 
(DCIS) or early stage breast cancer. To capture the maximum potential benefit of CPM 
we modeled invasive breast cancer only as this would impact survival and used CBC 
probabilities reported by Quan et al. [27] after excluding DCIS.  We estimated that the 
probability of developing stage I CBC was 67%, stage II was 24%, stage III was 5%, and 
stage IV was 4%. We used the stage distribution reported by SEER for primary breast 
cancer presentation in a sensitivity analysis (Table 1). [22]  
Effectiveness of Contralateral Prophylactic Mastectomy.  Several studies have 
demonstrated that CPM is effective in reducing the risk of CBC (relative risk reduction: 
83% to 97%). [10-14] We assumed that CPM reduced the annual risk of CBC by 90% in 
our base-case analysis.  Because breast cancer surgery is associated with a very small risk 
of mortality,[28, 29] we did not incorporate surgical mortality into our model.  
We assumed that the survival rates were the same after mastectomy as compared 
with lumpectomy and radiation for treatment of the affected breast. [30] Thus, all the 
  5 
survival benefit of bilateral mastectomies (i.e., CPM) is obtained from removing the 
unaffected contralateral breast.   
Sensitivity Analysis 
We performed sensitivity analyses to assess the stability of results to variation in the 
base-case parameter estimates.  The variables analyzed in the sensitivity analysis 
included probability of CBC, stage of CBC, and effectiveness of CPM.  When several 
published point estimates were available for a particular parameter, we evaluated the full 
range of published estimates.  In instances in which there were limited available 
published data and uncertainty for a variable estimate (e.g., stage of CBC), we varied our 
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RESULTS 
Impact of CPM on LE 
The predicted remaining LE’s for women undergoing CPM and no CPM are presented 
according to age, stage, and ER status at primary breast cancer diagnosis (Table 2).  LE 
gain from CPM ranged from 0.13 to 0.59 years for women with stage I breast cancer and 
0.08 to 0.29 years for those with stage II breast cancer.  CPM was more beneficial among 
younger women and those with stage I and ER-negative breast cancer.   Forty year-old 
women with stage I ER-negative breast cancer will live on average 36.44 years with no 
CBC and 0.32 years with CBC (lifetime risk of CBC is 1.8%) if they choose CPM; if 
they did not choose CPM, they would live 33.20 years with no CBC and 2.97 years with 
CBC (lifetime risk of CBC is 16.4%). Thus, while women will live on average 0.59 years 
longer with CPM than without, much of that time is spent without CBC and with only the 
negative impact of CPM. The potential benefit of CPM was consistently lower for 
patients with stage II breast cancer because of the worse prognosis associated with the 
primary breast cancer.  Similarly, the potential benefits of CPM are more modest for 
older women because they have relatively fewer years of remaining LE.  Sixty-year-old 
women will gain less than 2 months in LE from CPM whereas 40-year-old women will 
gain as much as 7 months.  CPM for ER-negative breast cancer patients is more 
beneficial as the probability of developing a CBC is higher amongst these women 
compared to ER-positive breast cancer patients.  
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Impact of CPM on survival 
The predicted absolute 10 and 20-year survival differences projected for CPM vs. no 
CPM are shown in Table 2.  Twenty-year survival differences ranged from 0.56% to 
0.94% for women with stage I breast cancer and 0.36% to 0.61% for women with stage II 
breast cancer, depending on age and ER status.  No cohort of women had a greater than 
1% absolute survival difference at 20 years.   
The predicted absolute 10 and 20-year disease-free survival differences are shown 
in Table 2.  Twenty-year disease free survival differences ranged from 4.25% to 7.20% 
for women with stage I breast cancer and 2.73% to 4.62% for women with stage II breast 
cancer, depending on age and ER status.  The overall survival and disease-free survival 
curves for 40-year-old women with stage I breast cancer are shown in Figure 2. 
Sensitivity Analyses 
CPM and CBC 
The predicted absolute 20-year survival differences for 40 year-old women with stage I 
breast cancer with varying probabilities of CBC (annual risk of 0.2% to 0.7%) and CPM 
effectiveness (80% to 100%) are shown in Figure 3.  Greater survival benefits were seen 
with greater CPM effectiveness and with a higher annual probability of developing CBC.   
The largest absolute survival difference was 1.45% when the CPM effectiveness was 
100% and the annual probability of developing CBC was 0.7% per year.  
Similar findings were observed when varying age and stage. The survival benefit 
ranged from 0.22% to 0.93% for 40-year-old women with stage II breast cancer; 0.31% 
to 1.3% and 0.20% to 0.86% for 50-year-old women with stage I or II breast cancer, 
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respectively; and 0.25% to 1.06% and 0.16% to 0.68% for 60-year-old women with stage 
I and II breast cancer, respectively.    
Projected survival benefit from CPM was more sensitive to variations in the risk 
of CBC than variations in the effectiveness of CPM.  For example, for 40-year-old 
women with stage I breast cancer, the survival difference ranged from 0.81% to 1.03% 
when varying the risk of CBC at constant CPM effectiveness; whereas varying CPM 
effectiveness at constant annual probability of developing CBC resulted in survival 
differences ranging from 0.09% to 0.3%.  
Stage of CBC 
We varied the probability of developing CBC stage I from 67% to 47%, stage II from 
24% to 41%, stage III from 5% to 7%, and stage IV from 4% to 5%.  Using these 
parameters, the predicted 20-year absolute survival difference for 40-year-old women 
with stage I ER-negative breast cancer changed from 0.94% (base-case) to 1.30%; ER-
positive breast cancer changed from 0.76% to 1.04%.  Similar 20-year survival changes 
were observed when varying age, stage, and ER status; although these differences were 
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DISCUSSION 
In this analysis, we assumed that the only plausible way that CPM improves breast cancer 
survival is by preventing a potentially fatal CBC. In 2011, the EBCTCG [26] reported 
that the annual rate of invasive CBC was about 0.4% for patients with ER-positive breast 
cancer treated with tamoxifen and 0.5% for patients with ER-negative breast cancer.  All 
age, tumor, and treatment subgroups had annual rates less than 0.7%.  Thus, the 10-year 
cumulative risk of CBC is about 4-5%.  
The risk of CBC may be even lower for patients diagnosed today.  Nichols et al. 
[31] reported that the rates of metachronous CBC have significantly decreased since 1985 
largely because of adjuvant systemic therapies.  The risk of CBC for postmenopausal 
women with ER-positive breast cancer may be lower yet because of the increased use of 
aromatase inhibitors.  In the Arimidex, Tamoxifen, Alone or in Combination (ATAC) 
trial, the 10-year cumulative incidence of CBC for women treated with anastrozole was 
only 3.2%. [25] 
In addition to the risk of CBC, the potential survival benefit of CPM also depends 
upon the mortality of the index cancer.  In our analysis, we found that the LE gain after 
CPM was lower for patients with higher stage tumors.  Although we didn’t model co-
morbidities, the potential survival benefit of CPM would be less for patients with other 
competing mortality factors.  Also, the stage and mortality of the CBC impacts the 
potential survival benefit of CPM. The stage of metachronous CBC is usually lower than 
that of the index cancer.  Using a state cancer registry, Quan et al. [27] reported that more 
than 90% of metachronous cancers were either stage I or II.  
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Several studies have demonstrated that CPM reduces the risk of CBC by about 
90%. [10-14], but the potential survival benefit is unclear.  A recently published 
Cochrane analysis concluded that “there is insufficient evidence that CPM improves 
survival.” [17] Yet, several retrospective studies have reported a survival benefit after 
CPM for selected patients.  Using the SEER database, Bedrosian et al. [15] reported that 
CPM was associated with a 4.8% absolute improvement in 5-year breast cancer-specific 
survival in young women with early-stage ER-negative breast cancer.  In a retrospective 
single-center study, Boughey et al. [16] reported that CPM was associated with a 9% 
absolute improvement in 10-year overall survival.  In another retrospective single-center 
study, Peralta et al. [13] reported a 15% absolute improvement in 15-year overall 
survival.  The absolute improvement in overall survival associated with CPM in these 
studies paradoxically exceeds the expected cumulative incidence of CBC.  
The survival benefit reported in our decision analysis was considerably lower than 
the results of retrospective single-center and cancer database studies.  We could identify 
no cohort in which CPM was associated with a 1% absolute improvement in 20-year 
survival.  The performance of sensitivity analyses varying the rates of CBC, stage of 
CBC, and CPM effectiveness yielded a maximum survival benefit of only 1.45% at 20 
years.  We found that the maximum 5- and 10-year absolute survival benefit from CPM 
was 0.09% and 0.31%, respectively.  In contrast, the EBCTCG [32] reported the 5- and 
10-year absolute survival benefit from adjuvant chemotherapy in estrogen poor breast 
cancer was 5% and 8%, respectively. 
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Selection bias markedly limits the ability to compare survival rates between CPM 
and no CPM patients in retrospective and cancer registry studies.  Patient, tumor, and 
treatment characteristics differ significantly between those who undergo CPM and those 
who do not.  Patients undergoing CPM are generally younger, more likely to be white, 
have higher education level, have private insurance, and have a family history of breast 
cancer. [1, 4, 5, 33] Tumor characteristics such as infiltrating lobular histology, 
multicentric disease, and lower breast cancer stage are also associated with higher CPM 
rates. [4, 5, 34, 35] Finally, patients undergoing CPM are more likely to receive a breast 
MRI, to undergo genetic testing, to receive breast reconstruction, and to be treated at a 
comprehensive cancer program or teaching institution. [1, 5, 33, 35] Similarly, patients 
who undergo more aggressive surgery are probably healthier and more likely to receive 
adjuvant therapy.  These differences likely explain the paradox of the CPM survival 
advantage exceeding the cumulative risk of CBC in retrospective studies.   
Our analysis has several limitations.  These results do not apply to BRCA gene 
mutation carriers with unilateral breast cancer who have a cumulative 10-year risk of 
CBC of about 30% to 40%. [36] The outcomes of this analysis were limited to overall 
and disease-specific survival; we did not evaluate other important outcomes such as 
surgical complications and quality of life.  Also, we assumed the mortality of CBC was 
the same as the mortality of the index cancer reported by SEER; we added these 
mortalities into our model once a woman developed CBC.  SEER mortality rates include 
mortality from CBC, and therefore, we may overestimate the mortality rates in our 
model.  Nevertheless, when comparing survival curves, they are very similar to SEER 
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and likely have little impact on the survival estimates that we found.  Another limitation 
is potential variation in the sources used for our model input.  However, the EBCTCG 
studies and the SEER database use large populations, which likely limits the extent of 
variation. 
Survival is only one potential benefit of a cancer risk-reduction strategy; effects 
on cancer-related anxiety, cosmesis, and self-image are also important in decision-
making processes.  For some women, the negative impact of CPM on quality of life may 
outweigh a potential survival benefit.  For others who are very anxious about CBC, CPM 
may result in a psychological benefit even if survival benefits are minimal.  Other 
investigators have reported quality of life utilities (numbers that represent the strength of 
an individual’s preference) for breast conserving surgery, double mastectomy, and CBC. 
[37, 38] Because of the relatively long time spent without CBC with CPM the difference 
between the utilities for CPM and no CPM have a large effect on quality adjusted life 
years (QALY’s) for the two strategies.  Decision-making parameters that would increase 
the likelihood of choosing CPM would be a lower utility for CBC and no CPM, and a 
higher utility for CPM.  If a woman places about a 3% decrease in the utility for CPM vs. 
no CPM the QALY’s would favor no CPM (data not shown).  Because our decision 
model is intended to facilitate decision-making by individuals, we have not adjusted for 
quality of life, as utility values are highly variable between women.  We present our 
results in terms of LE and survival differences to help individual women incorporate 
these effects and make personal assessments of how these interventions would affect their 
lives. 
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One prospective survey study reported that women with newly diagnosed breast 
cancer substantially overestimated their risk of developing CBC. [9] Another survey 
study suggested that breast cancer patients have unrealistic expectations of the benefits of 
CPM. [39] Perhaps, these perceptions partially explain the dramatic increase in CPM 
rates observed in the United States.  Survival estimates derived from our model may be 
useful for physicians and breast cancer patients to arrive at evidence-based informed 
decisions regarding CPM.  Moreover, the use of accurate and easily understood decision 
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Figure 1: Markov Model. Abbreviations: ER, estrogen receptor; CPM, contralateral 
prophylactic mastectomy; CBC, contralateral breast cancer.  Women in each Markov 
state (no CBC, CBC stage I, CBC stage II, CBC stage III, CBC stage IV) can die from 
other causes or die from breast cancer.  Each cycle of the Markov model is one year.  The 
model ran the lifetime of the cohort.  For example, the model predicting life expectancy 
in the 40 year-old cohort ran 61 cycles to obtain data through age 100 (lifetime).  The 
model predicting life expectancy for the 50 year-old cohort ran 51 cycles and the model 
for the 60 year-old cohort ran 41 cycles.  To generate 20-year survival curves we only 
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Table 1.  Base-Case Probabilities and Ranges Evaluated in Sensitivity Analysis 
Variable % (Range) Source 
Primary breast cancer 
     10-year disease specific mortality  
            Stage I 
            Stage II 
            Stage III 









Contralateral breast cancer 
      Yearly incidence 
            Hormone receptor positive 
            Hormone receptor negative 
      Disease stage at diagnosis 
            Stage I 
            Stage II 
            Stage III 
















Contralateral prophylactic mastectomy 





Table 2:  Predicted Life Expectancy Gains, Absolute Survival Difference, and Absolute 
Disease- Free Survival Difference from Contralateral Prophylactic Mastectomy 
 Life Expectancy (yrs) 20 year (10 year) Survival (%) 





40 yo, ER+, Stage I 36.77 36.30 0.47 0.76 (0.25) 5.81 (3.39) 
40 yo, ER-, Stage I 36.76 36.17 0.59 0.94 (0.31) 7.20 (4.22) 
40 yo, ER+, Stage 2 24.16 23.92 0.24 0.49 (0.20) 3.73 (2.66) 
40 yo, ER-, Stage 2 24.15 23.86 0.29 0.61 (0.25) 4.62 (3.30) 
50 yo, ER+, Stage 1 29.72 29.45 0.27 0.70 (0.25) 5.33 (3.31) 
50 yo, ER-, Stage 1 29.71 29.38 0.33 0.87 (0.31) 6.60 (4.12) 
50 yo, ER+, Stage 2 20.89 20.74 0.15 0.45 (0.19) 3.43 (2.60) 
50 yo, ER-, Stage 2 20.88 20.70 0.18 0.56 (0.24) 4.24 (3.22) 
60 yo, ER+, Stage 1 22.54 22.41 0.13 0.56 (0.23) 4.25 (3.11) 
60 yo, ER-, Stage 1 22.53 22.37 0.16 0.69 (0.29) 5.26 (3.87) 
60 yo, ER+, Stage 2 16.98 16.90 0.08 0.36 (0.18) 2.73 (2.44) 
60 yo, ER-, Stage 2 16.98 16.88 0.10 0.44 (0.23) 3.38 (3.03) 
Abbreviations:  CPM, contralateral prophylactic mastectomy; LE, life expectancy;  






















Figure 2: Twenty-year predicted overall survival and disease-free survival in 40 year-old 
women with stage I breast cancer. A, Overall survival in estrogen receptor negative stage 
I breast cancer.  B, Disease-free survival in estrogen receptor negative stage I breast 
cancer.  C, Overall survival in estrogen receptor positive stage I breast cancer.   D, 
Disease-free survival in estrogen receptor positive stage I breast cancer. 




Figure 3.  Sensitivity analysis on predicted twenty-year absolute survival difference in 
40-year old women with stage I breast cancer with varying annual probabilities of 
developing contralateral breast cancer (CBC) and effectiveness of contralateral 
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Abbreviations:  stage, variable used for stage of breast cancer; _STAGE, model counter, 
each cycle is one year, for example first cycle time = 0, second cycle time = 1. 
ER, estrogen receptor; CPM, contralateral prophylactic mastectomy; 
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brcamort, Breast Cancer Mortality Table: 
Time 
(years) 
Stage 1 Stage 2 Stage 3 Stage 4 
1 0 0.007024615 0.087738914 0.515838166 
2 0.0010005 0.029639369 0.14167425 0.328131905 
3 0.001001502 0.03375848 0.125834228 0.304883435 
4 0.002006019 0.033827557 0.10837663 0.257643563 
5 0.002010051 0.032715834 0.09150186 0.233400051 
6 0.003022672 0.026730238 0.085428848 0.186453794 
7 0.002020203 0.027464413 0.076885143 0.168749479 
8 0.002024292 0.024511031 0.056917363 0.150480951 
9 0.002028398 0.021317422 0.064972455 0.157003749 
10 0.003050333 0.025675351 0.057158414 0.116533816 
11+ 0.008719655 0.02855171 0.037291251 0.077214113 
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66 0.011838922 
67 0.012979695 
68 0.014178268 
69 0.015473447 
70 0.016880352 
71 0.018547232 
72 0.02047223 
73 0.022630014 
74 0.024950558 
75 0.027424561 
76 0.030211367 
77 0.033370463 
78 0.037086502 
79 0.041297081 
80 0.045886804 
81 0.050882598 
82 0.056705728 
83 0.063777195 
84 0.071586555 
85 0.080427769 
86 0.090940935 
87 0.102714297 
88 0.115824094 
89 0.130373073 
90 0.146459453 
91 0.164173422 
92 0.183592933 
93 0.20477919 
94 0.227771802 
95 0.252584036 
96 0.279198097 
97 0.307561326 
98 0.337583002 
99 0.369133107 
100 1000 
 
 
 
 
